Mabqi logo

Mabqi

Your key partner for breakthrough antibody discovery

26 employees · est. 2017 · Grabels, France

VS
Symphogen logo

Symphogen

188 employees · est. 2000 · Ballerup, Denmark

Symphogen is the older company (2017 vs 2000); Symphogen is the larger of the two.

Side-by-Side Comparison

Mabqi Symphogen
Founded
2017 2000 older
Headquarters
Grabels, France Ballerup, Denmark
Employees
26 188 larger
Industry
Biotechnology Biopharma, Biotechnology, Pharmaceutical
Funding Stage
Not tracked yet Debt Financing
Total Funding
Not tracked yet $314.00M
Funding Rounds
Not tracked yet 10
Services
Discovery and development of fully human antibodies, Antibody Drug Discovery, Antibody Maturation, LiteMab Antibody Discovery Studio services Not tracked yet
Target Customers
Pharmaceutical Companies, Biotechnology Firms, Oncology Researchers, Clinical Research Organizations Not tracked yet
Taxonomy
Antibody Discovery, Fully Human Antibody Discovery, Therapeutic Antibodies, Oncology Applications, Antibody Affinity Maturation, Antibody Optimization, PH-Sensitive Antibodies, Monoclonal Antibodies, Multispecific Antibodies, Synthetic Antibody Library, Phage Display, Yeast Display, Antibody Development, Immuno-Oncology, Bispecific Antibodies Biologics Development, Antibodies, Oncology, Immune-oncology, R&D Strategy, Clinical Stages, Compounds, Therapies, Cancer Treatment, Drug Development
Website
mabqi.com symphogen.com
Mabqi logo

About Mabqi

Mabqi, founded in 2017 and headquartered in France, is emerging as a pivotal player in the Biotechnology industry with its cutting-edge approaches to antibody discovery. Under its slogan, "Your key partner for breakthrough antibody discovery," the company leverages proprietary technology, employing...

Symphogen logo

About Symphogen

Symphogen: Symphogen A/S, a Servier company and the Centre of Excellence for Antibodies, operates within in research, early clinical stages and CMC biologics development from research to market. Supporting Servier’s commitment to improve patients health and the R&D strategy within oncology and immun...

We will tell you when either one moves

BounceWatch watches Mabqi and Symphogen for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Mabqi and Symphogen — by email.

Frequently Asked Questions

Mabqi — Your key partner for breakthrough antibody discovery. Symphogen. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Mabqi has raised undisclosed funding while Symphogen has raised $314.00M.
Mabqi and Symphogen operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Mabqi with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Mabqi on 11 Mar 2026, and Symphogen on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy